Achilles Therapeutics PLC
(FRA:698)
€
0.71
0 (0%)
Market Cap: 30.32 Mil
Enterprise Value: -69.29 Mil
PE Ratio: 0
PB Ratio: 0.27
GF Score: 34/100 - Achilles Therapeutics PLC at Chardan Genetic Medicines & Cell Therapy Manufacturing Summit (Virtual) TranscriptApr 24, 2023
- Achilles Therapeutics PLC at Oppenheimer Healthcare Conference (Virtual) TranscriptMar 14, 2023
- Achilles Therapeutics PLC at Eqt Life Sciences BioCapital Europe TranscriptMar 09, 2023
- Achilles Therapeutics PLC at JPMorgan Healthcare Conference TranscriptJan 12, 2023
- Achilles Therapeutics PLC ESMO IO Webcast Call TranscriptDec 06, 2022
- Achilles Therapeutics PLC at Bank of America Healthcare Conference TranscriptMay 11, 2022
- Achilles Therapeutics PLC to Highlight TRACERx Study Presentations from the 2022 AACR Annual Meeting - Fireside Chat TranscriptApr 14, 2022
- Achilles Therapeutics PLC at Needham Healthcare Conference (Virtual) TranscriptApr 12, 2022
- Achilles Therapeutics PLC SITC and Corporate Update Call TranscriptNov 12, 2021
Achilles Therapeutics PLC at Bank of America Healthcare Conference Transcript
May 11, 2022 / 11:00PM GMT
Release Date Price:
€1.87
(+4.47%)
Tazeen Ahmad
BofA Securities, Inc. - Analyst
Can you hear me? So good afternoon. I am Tazeen Ahmad. I am one of the senior SMid biotech analysts here at Bank of America. It's my pleasure to have our next presenting company at the conference on day two, Achilles Therapeutics.
Sitting next to me is CEO, Iraj Ali. Iraj, thank you so much for coming.
Iraj Ali
Achilles Therapeutics plc - CEO
Thank you (multiple speakers)
Tazeen Ahmad
BofA Securities, Inc. - Analyst
Thanks for making a trip from London.
Iraj Ali
Achilles Therapeutics plc - CEO
Yeah. No, delighted to be here.
Tazeen Ahmad
BofA Securities, Inc. - Analyst
So we usually like to start off with an overview of the company. So if you want to take a few minutes to educate those who aren't as familiar with the company about the platform, some of the recent catalysts and what to expect, that would be great. And then we can go forward from there, some Q&A.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)